Who is eligible for clinical trial NCT01081951?

Participants must meet protocol criteria for Ovarian Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT01081951 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-04

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer (NCT01081951)

A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

Who can join: Review the eligibility criteria below.

Location: Research Site — Stanford, California

Age range: 18 Years to 125 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (53 Sites)

Showing the first 25 of 53 sites.

Research Site — Stanford, California
Research Site — West Hollywood, California
Research Site — Orlando, Florida
Research Site — Indianapolis, Indiana
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — New York, New York
Research Site — Portland, Oregon
Research Site — Parkville,
Research Site — Randwick,
Research Site — Brussels,
Research Site — Leuven,
Research Site — Namur,
Research Site — Wilrijk,
Research Site — Vancouver, British Columbia
Research Site — Hamilton, Ontario
Research Site — Toronto, Ontario
Research Site — Toronto, Ontario
Research Site — Québec, Quebec
Research Site — Sherbrooke, Quebec
Research Site — Brno,
Research Site — Brno,
Research Site — Hradec Králové,
Research Site — Olomouc,
Research Site — Prague,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts

Explore by condition: All Ovarian Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗